Comparative Pharmacology
Head-to-head clinical analysis: ENSTILAR versus EXEM FOAM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSTILAR versus EXEM FOAM KIT.
ENSTILAR vs EXEM FOAM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
The active ingredient in EXEM FOAM KIT is diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
Apply to affected area twice daily. Exemestane is an aromatase inhibitor; this is a topical formulation.
None Documented
None Documented
Calcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Terminal elimination half-life is approximately 5–6 hours in patients with normal renal function; prolonged in hepatic impairment.
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Primarily fecal via biliary elimination (>90% as unchanged drug and metabolites); renal excretion accounts for <10%.
Category C
Category C
Topical Corticosteroid and Vitamin D Analog
Topical Corticosteroid